Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 17/20 | 0.78 |
| ▸ | SLC6A4 | P31645 | 17/20 | 0.78 |
| ▸ | SLC6A3 | Q01959 | 17/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4306070 | 0.88 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL4307689 | 0.79 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL20863593 | 0.79 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3CYP2D6HSD11B1 | |
| SCHEMBL4305781 | 0.78 | SLC6A2 (0.73) | SLC6A2SLC6A4SLC6A3CYP2D6CHRM1 | |
| SCHEMBL4272851 | 0.77 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3CYP2D6HSD11B1 | |
| SCHEMBL4282018 | 0.77 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3CYP2D6HSD11B1 | |
| SCHEMBL4272848 | 0.77 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3CYP2D6HSD11B1 | |
| SCHEMBL14571687 | 0.76 | SLC6A4 (0.53) | SLC6A2SLC6A4SLC6A3CYP2D6CHRM1 | |
| SCHEMBL1245816 | 0.76 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL1247171 | 0.76 | SLC6A2 (0.71) | SLC6A2SLC6A4SLC6A3CYP2D6CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622462-B2 | Benzazepine derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-11-24 | — | — | US | disclosed |
| US-20070281920-A1 | Benzazepine derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281920-A1 | Benzazepine derivatives and uses thereof | TPH1, TPH2, HTR2B | SLC6A2 31/4885SLC6A4 29/4885SLC6A3 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.